Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Elihu Estey

Showing results (1-10 of 158) with videos related to

Pageof 16
Sort By:
Best Practice & Research. Clinical Haematology|December 3, 2014
Management of persistent AML at day 14Elihu Estey
Hematology. American Society of Hematology. Education Program|January 18, 2011
High cytogenetic or molecular genetic risk acute myeloid leukemiaElihu Estey
Seminars in Oncology|August 12, 2008
New drugs in acute myeloid leukemiaElihu Estey
Mediterranean Journal of Hematology and Infectious Diseases|August 13, 2013
Therapeutic Options for Patients who are not Eligible for Intensive ChemotherapyElihu Estey
Lancet (London, England)|April 10, 2012
Treatment of AML: resurrection for gemtuzumab ozogamicin?Elihu Estey
Best Practice & Research. Clinical Haematology|November 29, 2016
Why are there so few randomized trials for patients with primary refractory acute myeloid leukemia?Elihu Estey
Advances in Pharmacology (San Diego, Calif.)|October 7, 2004
Methodologic issues in investigation of targeted therapies in acute myeloid leukemiaElihu Estey
Blood|February 12, 2011
The times they are a-changin'Elihu Estey
Seminars in Hematology|June 27, 2015
Why Is Progress in Acute Myeloid Leukemia So Slow?Elihu Estey
Haematologica|October 2, 2009
Do commonly used clinical trial designs reflect clinical reality?Elihu Estey
Pageof 16

Showing results (1-10 of 158) with videos related to

Sort By:
Pageof 16
Best Practice & Research. Clinical Haematology|December 3, 2014
Management of persistent AML at day 14Elihu Estey
Hematology. American Society of Hematology. Education Program|January 18, 2011
High cytogenetic or molecular genetic risk acute myeloid leukemiaElihu Estey
Seminars in Oncology|August 12, 2008
New drugs in acute myeloid leukemiaElihu Estey
Mediterranean Journal of Hematology and Infectious Diseases|August 13, 2013
Therapeutic Options for Patients who are not Eligible for Intensive ChemotherapyElihu Estey
Lancet (London, England)|April 10, 2012
Treatment of AML: resurrection for gemtuzumab ozogamicin?Elihu Estey
Best Practice & Research. Clinical Haematology|November 29, 2016
Why are there so few randomized trials for patients with primary refractory acute myeloid leukemia?Elihu Estey
Advances in Pharmacology (San Diego, Calif.)|October 7, 2004
Methodologic issues in investigation of targeted therapies in acute myeloid leukemiaElihu Estey
Blood|February 12, 2011
The times they are a-changin'Elihu Estey
Seminars in Hematology|June 27, 2015
Why Is Progress in Acute Myeloid Leukemia So Slow?Elihu Estey
Haematologica|October 2, 2009
Do commonly used clinical trial designs reflect clinical reality?Elihu Estey
Pageof 16